Replies to post #423955 on Amarin Corp Plc (AMRN)

[Whalatane]

Based on the search results, here are the key things Amarin would need to do to get reimbursement for Vazkepa (icosapent ethyl) in Germany:

Reach a viable agreement with the National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement price for Vazkepa:
The search results indicate that after four rounds of negotiations, Amarin and the GKV-SV were unable to reach an agreement on the reimbursement price.
The matter was escalated to the Arbitration Board for a final decision, as the two parties could not come to terms.

Potentially use real-world evidence and data to support the clinical benefits of Vazkepa:
The search results mention that there is a precedent in Germany where a product that received a negative reimbursement decision was able to get it reversed by using real-world evidence and data to demonstrate the clinical benefits.
Amarin indicated they may explore a similar path to resubmit the file in Germany.

etc
Kiwi